CytomX Therapeutics Net Worth
CytomX Therapeutics Net Worth Breakdown | CTMX |
CytomX Therapeutics Net Worth Analysis
CytomX Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including CytomX Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of CytomX Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform CytomX Therapeutics' net worth analysis. One common approach is to calculate CytomX Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares CytomX Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing CytomX Therapeutics' net worth. This approach calculates the present value of CytomX Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of CytomX Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate CytomX Therapeutics' net worth. This involves comparing CytomX Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into CytomX Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if CytomX Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding CytomX Therapeutics' net worth research are outlined below:
| CytomX Therapeutics generated a negative expected return over the last 90 days | |
| CytomX Therapeutics has some characteristics of a very speculative penny stock | |
| CytomX Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 101.21 M. Net Loss for the year was (569 K) with profit before overhead, payroll, taxes, and interest of 53.16 M. | |
| CytomX Therapeutics currently holds about 194.29 M in cash with (56.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| CytomX Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 66.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from zacks.com: JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer |
CytomX Therapeutics Quarterly Good Will |
|
CytomX Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in CytomX Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to CytomX Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 25th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 25th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know CytomX Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as CytomX Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading CytomX Therapeutics backward and forwards among themselves. CytomX Therapeutics' institutional investor refers to the entity that pools money to purchase CytomX Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Rtw Investments, Llc | 2024-06-30 | 1.2 M | Blackrock Inc | 2024-06-30 | 1.1 M | Renaissance Technologies Corp | 2024-09-30 | 1 M | Altium Capital Management, Lp | 2024-09-30 | 915 K | Adar1 Capital Management Llc | 2024-09-30 | 904 K | Geode Capital Management, Llc | 2024-09-30 | 803.5 K | Two Sigma Investments Llc | 2024-09-30 | 471.5 K | Sei Investments Co | 2024-06-30 | 382.7 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 377 K | Tang Capital Management Llc | 2024-09-30 | 7.8 M | Hhg Plc | 2024-06-30 | 6.3 M |
Follow CytomX Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 82.95 M.Market Cap |
|
Project CytomX Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Capital Employed | (0.14) | (0.15) | |
| Return On Equity | 0.01 | 0.01 |
When accessing CytomX Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures CytomX Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of CytomX Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in CytomX Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of CytomX Therapeutics. Check CytomX Therapeutics' Beneish M Score to see the likelihood of CytomX Therapeutics' management manipulating its earnings.
Evaluate CytomX Therapeutics' management efficiency
CytomX Therapeutics has return on total asset (ROA) of 0.0233 % which means that it generated a profit of $0.0233 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (54.7503) %, meaning that it created substantial loss on money invested by shareholders. CytomX Therapeutics' management efficiency ratios could be used to measure how well CytomX Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 0.01 in 2024, whereas Return On Tangible Assets are likely to drop (0) in 2024. At this time, CytomX Therapeutics' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 19.5 M in 2024, whereas Other Assets are likely to drop slightly above 1 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.64) | (0.61) | |
| Tangible Book Value Per Share | (0.67) | (0.63) | |
| Enterprise Value Over EBITDA | (25.81) | (24.52) | |
| Price Book Value Ratio | (2.41) | (2.29) | |
| Enterprise Value Multiple | (25.81) | (24.52) | |
| Price Fair Value | (2.41) | (2.29) | |
| Enterprise Value | 111.2 M | 105.6 M |
CytomX Therapeutics has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Enterprise Value Revenue 0.0156 | Revenue 126.6 M | Quarterly Revenue Growth 0.267 | Revenue Per Share 1.518 | Return On Equity (54.75) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CytomX Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on CytomX Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases CytomX Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
CytomX Therapeutics time-series forecasting models is one of many CytomX Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary CytomX Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
CytomX Therapeutics Earnings per Share Projection vs Actual
CytomX Therapeutics Corporate Management
| JD Rowland | General VP | Profile | |
| MBA BS | Head VP | Profile | |
| Danielle OlanderMoghadassian | Senior Officer | Profile | |
| YuWaye MD | Senior Officer | Profile | |
| Christopher Ogden | Principal Accounting | Profile |
Additional Tools for CytomX Stock Analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.